Scinai Immunotherapeutics Ltd ADR Dossier
Qualitative Analysis
Business overview
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), formerly known as BiondVax Pharmaceuticals Ltd., is an Israel-based, clinical-stage biopharmaceutical company focused on developing innovative immunology and immunotherapy products. The company operates a dual-business model. Its proprietary R&D pipeline is centered on the 'NanoAb' platform, which utilizes alpaca-derived nanosized VHH-antibodies to target inflammatory and autoimmune diseases, with its primary validation program focused on a systemic IL-17 bispecific antibody for plaque psoriasis. Additionally, Scinai is advancing PC111, a human monoclonal antibody licensed from PinCell S.r.l. for dermatological indications. Complementing its R&D, Scinai operates a boutique Contract Development and Manufacturing Organization (CDMO) through its subsidiary, Scinai Biopharma Services Ltd. (formerly Recipharm Israel Ltd.), providing end-to-end biological drug development, analytical services, and clinical cGMP manufacturing from facilities in Jerusalem and Yavne, Israel.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Completion of a strategic corporate reorganization establishing a dedicated CDMO platform (Scinai Biopharma Services Ltd.) alongside a streamlined R&D organization (Scinai Immunotherapeutics). This structure establishes a clear separation between the execution-focused CDMO business and the R&D organization focused on advancing innovative therapeutics.
Expected impact: Designed to enhance capital efficiency, improve operational focus, and position each business unit clearly for its respective stakeholders.
A project to advance a robotic aseptic fill & finish platform, utilizing a fully automated, versatile robotic-arm aseptic fill & finish system designed to align with EU GMP Annex 1 standards.
Expected impact: Supports the acquisition and validation of next-generation sterile manufacturing capabilities, enhancing the technological depth of Scinai's biologics offering in Jerusalem.
Prioritizing the development of a systemic IL-17 bispecific antibody program as the primary validation program for the Company's NanoAb platform, following scientific, commercial, and regulatory evaluation of multiple development paths.
Expected impact: Serves as the lead validation program for the proprietary NanoAb platform, targeting autoimmune and inflammatory diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of 100% of the shares of Recipharm Israel Ltd. (subsequently renamed Scinai Biopharma Services Ltd.), which operates a cGMP manufacturing site in Yavne, Israel, providing early chemistry development and small-scale manufacturing of active pharmaceutical ingredients (APIs). The transaction expands Scinai's capabilities beyond biologics into small-molecule development and manufacturing, establishing an integrated two-site CDMO platform.
Financial impact: Added approximately $6.2 million in net identifiable assets to Scinai's balance sheet, resulting in a non-cash bargain purchase gain of $6.2 million recognized in Q1 2026. The Yavne facility generated approximately $200,000 in revenue during Q1 2026 post-acquisition.
Strategic Partnerships
Establishes a long-term strategic commercial collaboration where Scinai serves as a preferred partner for early-stage development and clinical manufacturing within the Recipharm ecosystem, while Recipharm serves as a preferred partner for late-stage clinical and commercial manufacturing. This provides Scinai's clients with a seamless 'graduation' pathway to late-stage and commercial production via Recipharm's global network, and allows Scinai to participate economically in graduated programs.
Terms: Includes structured referral economics, joint marketing and business development initiatives, and defined name-rights provisions under predefined commercial terms.
Ongoing strategic collaboration activities for the discovery, initial characterization, development, and commercialization of innovative nanosized VHH antibody fragments (NanoAbs) targeting autoimmune and inflammatory diseases.
Terms: Engaged in discussions regarding the expansion and amendment of existing license arrangements.